Preclinical Development SKLB 1206 , a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T 790 M Mutants , ErbB 2 , ErbB 4 , and VEGFR 2 , Displays Potent Antitumor Activity Both In Vitro and In Vivo

@inproceedings{Pan2012PreclinicalDS,
  title={Preclinical Development SKLB 1206 , a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T 790 M Mutants , ErbB 2 , ErbB 4 , and VEGFR 2 , Displays Potent Antitumor Activity Both In Vitro and In Vivo},
  author={Youli Pan and Shan Feng and Shidong Luo and Renlin Zheng and Jiao L Yang and Lei Zhong and Han-Yu Yang and Bing-Lin Wang and Jingjing Liu and Zhixing Cao and Xiaoyan Wang and Zerong Wang and Yu-Quan Wei and Shengyong Yang},
  year={2012}
}
Anti-epidermal growth factor receptor (EGFR) treatment has been successfully applied in clinical cancer therapy. However, the clinical efficacy of first-generation reversible EGFR inhibitors, such as gefitinib and erlotinib, is limited by the development of drug-resistantmutations, including the gatekeeper T790Mmutation and upregulation of alternative signaling pathways. Second-generation irreversible EGFR inhibitors that were designed to overcome the drug resistance due to the T790Mmutation… CONTINUE READING
1 Citations
47 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 47 references

Cooperative signaling of ErbB3 and ErbB2 in neoplastic Preclinical Studies of Antitumor Agent SKLB1206 www.aacrjournals.org Mol Cancer Ther

  • M Alimandi, A Romano, MC Curia, R Muraro, P Fedi, SA Aaronson
  • April 2012 961 on July
  • 2012

Similar Papers

Loading similar papers…